Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 8/20 | 0.58 |
| ▸ | ATR | Q13535 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13169723 | 0.86 | P2RX7 (0.56) | PRKCIATRGRM5P2RX7KDM4E | |
| SCHEMBL1230868 | 0.81 | PRKCI (0.56) | PRKCIATRGRM5TLR7KDM4E | |
| SCHEMBL3410605 | 0.80 | PRKCI (0.48) | PRKCIATRGRM5TLR7KDM4E | |
| SCHEMBL28119884 | 0.78 | P2RX7 (0.48) | PRKCIATRP2RX7KDM4EPKM | |
| SCHEMBL5779813 | 0.77 | P2RX7 (0.47) | PRKCIATRP2RX7KDM4EPKM | |
| SCHEMBL30078211 | 0.77 | P2RX7 (0.47) | PRKCIATRGRM5TLR7P2RX7 | |
| SCHEMBL31589622 | 0.77 | P2RX7 (0.47) | PRKCIATRGRM5P2RX7KDM4E | |
| SCHEMBL3461907 | 0.77 | P2RX7 (0.55) | PRKCIP2RX7KDM4E | |
| SCHEMBL31646760 | 0.77 | P2RX7 (0.47) | PRKCIATRP2RX7KDM4EPKM | |
| SCHEMBL27669301 | 0.77 | PRKCI (0.50) | PRKCIATRGRM5TLR7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109721592-B | Fluorescent probe containing aminopyrazine acylhydrazone derivatives of coumarin as well as preparation method and application of fluorescent probe | 河南理工大学 | 2022-09-30 | — | — | CN | claimed |
| CN-109810692-B | Fluorescent probe based on 3-aminopyrazine acylhydrazone derivative and preparation method and application thereof | 河南理工大学 | 2021-10-22 | — | — | CN | claimed |
| CN-109810692-A | A kind of fluorescence probe and its preparation method and application based on 3- Aminopyrazine acyl hydrazone derivative | 河南理工大学 | 2019-05-28 | — | — | CN | claimed |
| CN-109721592-A | A kind of fluorescence probe and its preparation method and application of the Aminopyrazine acyl hydrazone derivative containing cumarin | 河南理工大学 | 2019-05-07 | — | — | CN | claimed |
| CN-116285821-A | High-toughness Gao Jiangshan component epoxy structural colloid system with high storage stability and controllable reaction and preparation method thereof | 上海德联化工有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-109721592-B | Fluorescent probe containing aminopyrazine acylhydrazone derivatives of coumarin as well as preparation method and application of fluorescent probe | 河南理工大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-109810692-B | Fluorescent probe based on 3-aminopyrazine acylhydrazone derivative and preparation method and application thereof | 河南理工大学 | 2021-10-22 | — | — | CN | disclosed |
| CN-109810692-A | A kind of fluorescence probe and its preparation method and application based on 3- Aminopyrazine acyl hydrazone derivative | 河南理工大学 | 2019-05-28 | — | — | CN | disclosed |
| CN-109721592-A | A kind of fluorescence probe and its preparation method and application of the Aminopyrazine acyl hydrazone derivative containing cumarin | 河南理工大学 | 2019-05-07 | — | — | CN | disclosed |
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| WO-2014114928-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114928-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| EP-0217748-B1 | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof | CIBA-GEIGY AG (CH) | 1991-02-06 | — | — | EP | disclosed |
| US-4831013-A | BENZODIAZEPINE RECEPTOR ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1989-05-16 | — | — | US | disclosed |
| WO-1988002370-A1 | 2-SUBSTITUTED-E-FUSED-[1,2,4]TRIAZOLO[1,5-C]PYRIMIDINES PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CIBA-GEIGY AG (CH) | 1988-04-07 | — | — | WO | disclosed |
| EP-0263071-A1 | 2-Substituted-e-fused-[1,2,4]-triazolo[1,5-c] pyrimidines, pharmaceutical compositions, and uses thereof | CIBA-GEIGY AG (CH) | 1988-04-06 | — | — | EP | disclosed |
| EP-0217748-A2 | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof | CIBA-GEIGY AG (CH) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206700-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, TP53 | PRKCI 1127/4885ATR 2028/4885GRM5 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.